ACUPANTM - Medsafe
NEW ZEALAND DATA SHEET ACUPANTM ACUPANTM Page 3 of 5 4.9 Overdose Symptoms and Signs Nefopam toxicity is manifested by neurological symptoms ( coma, convulsions, hallucinations,
Download ACUPANTM - Medsafe
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
Spongiotic Dermatitis (compressed) - lasop.com
lasop.com2 Spongiotic Dermatitis • Select entities commonly encountered in daily practice – Nummular eczema – Contact dermatitis – Seborrheic dermatitis
Eritema multiforme. Revisión y puesta al día
scielo.isciii.esEritema multiforme. Revisión y puesta al día Erythema multiforme. Revision and update RCOE, 2004, Vol 9, Nº4, 415-423 – 415– Gavaldá-Esteve, Carmen*
ERYTHEMA MULTIFORME PATIENT INFORMATIN …
sussexcds.co.uk4 Fitzroy Sqaure, London W1T 5HQ Tel: 020 7383 0266 Fax: 020 7388 5263 e-mail: admin@bad.org.uk Registered Charity No. 258474 ERYTHEMA MULTIFORME PATIENT INFORMATIN LEAFLET
NeurotoP® anticonvulsant - antineuralgic …
www.bppharma.netanticonvulsant - antineuralgic Neurotop 200 mg tablets, Neurotop retard 300 mg tablets. Neurotop 400 mg tablets. Neurotop retard 600 mg tablets
Sindrome de la escaldadura estafilococica - Web …
www.webpediatrica.comGuerrero-Fernández J. Síndrome de la Escaldadura Estafilocócica. Web PEDiátrica 2002 Web PEDiatrica.com 2 algunos autores es sinónimo del verdadero SSSS
PATIENT INFORMATION LEAFLET Aspirin Tablets BP …
www.medicines.org.ukBLACK DIMENSIONS: 148 x 210mm Folded size 148 x 40mm PATIENT INFORMATION LEAFLET Aspirin Tablets BP 75 mg Please read all of this leaflet carefully
HIGHLIGHTS OF PRESCRIBING INFORMATION - …
www.merck.com3 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Newly Diagnosed Glioblastoma Multiforme TEMODAR® (temozolomide) is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment.